- Ongoing, recruitingTherapeutic exploratory (Phase II)
Optimizing reversal of HIV latency with combination therapy (pyrimethamine, lenalidomide, panobinostat)
This study is looking at a new combination of medicines to wake up 'sleeping' HIV in the body. By waking up the virus, the hope is that current treatments can then clear it more effectively. It's for adults with HIV-1, aiming to find better ways to manage the virus.
For: HIV-1Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
For: Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNetherlands · Spain · Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
This study looks at how long people with multiple myeloma, a type of blood cancer, continue taking elotuzumab or other treatments after being in an earlier study. It also checks for any side effects experienced.
For: Multiple MyelomaRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
This study looks at a new treatment combination called KRd for people with multiple myeloma whose scans still show some active cancer after their first treatment. We want to see if KRd can help these patients achieve better results, specifically if their scans become completely clear.
For: Multiple MyelomaDenmark · Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment
This study looks at a new combination of medicines, including isatuximab, for people newly diagnosed with multiple myeloma and kidney problems. Researchers want to see how well these treatments help reduce kidney damage and slow down the myeloma.
For: Newly diagnosed patients with multiple myeloma and severe renal impairmentGreece - RecruitingPHASE3
A Study of Daratumumab
This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.
For: Multiple MyelomaUnited States · Belgium · Brazil - Active not recruitingPHASE3
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
This study looks at whether adding two medicines, lenalidomide and dexamethasone, after radiotherapy for a type of bone cancer called solitary bone plasmacytoma, can stop it from turning into a more serious condition called multiple myeloma.
For: PlasmacytomaUnited Kingdom - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
This study compares two treatments for follicular lymphoma that has come back or not responded to previous treatments. It looks at a new drug, mosunetuzumab, combined with lenalidomide, versus a standard treatment, rituximab with lenalidomide, to see which works better and if they are safe.
For: Relapsed or Refractory Follicular LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at a new treatment, bb2121, for multiple myeloma that has come back or isn't responding to common medicines. It compares bb2121 with standard treatments to see which works best and is safest for patients aged 18 and over.
For: Multiple MyelomaUnited States · Belgium · Canada - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
This study is testing a new medicine called epcoritamab, sometimes with other treatments, for people with B-cell non-Hodgkin lymphoma. Doctors want to check if it's safe and if it helps shrink the cancer. It's given by injection under the skin.
For: Diffuse Large B-Cell Lymphoma · Follicular LymphomaUnited States · Australia · Belgium - RecruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - Active not recruitingPHASE3
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
This study looks at a new combination of two drugs, tafasitamab and lenalidomide, for adults in the UK with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It's for those whose cancer has returned or hasn't responded well to previous treatments and who can't have a stem cell transplant.
For: Large B-Cell Lymphoma · Diffuse Large B-Cell LymphomaBulgaria · Croatia · Czechia - RecruitingPHASE3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
This study looks at new treatments for multiple myeloma, a type of blood cancer. We're testing if teclistamab, alone or with lenalidomide, works better than lenalidomide alone after a stem cell transplant to stop the cancer from coming back.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
For: Plasma Cell MyelomaUnited States · Australia · Brazil - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
This study looks at a new drug, golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or not responded to previous treatments. It compares this new combination to standard treatments chosen by doctors.
For: Follicular LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
For: Follicular Lymphoma (FL)United States · Argentina · Australia - Active not recruitingPHASE2
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
This study looks at new treatments for a type of blood cancer called Diffuse Large B-Cell Lymphoma in older patients who can't have standard chemotherapy. It tests a drug called epcoritamab, with or without another drug called lenalidomide, to see how well they work and if they are safe.
For: Diffuse Large B-Cell LymphomaUnited States · Austria · Belgium - Active not recruitingPHASE3
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
This study looks at new treatments for multiple myeloma, a type of blood cancer. It compares a standard treatment plus a new cell therapy called cilta-cel, against the standard treatment alone, for people newly diagnosed who aren't having a stem cell transplant initially.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study looks into a new treatment for follicular lymphoma and marginal zone lymphoma that have returned or didn't respond to previous treatments. It combines a new drug, odronextamab, with an existing one, lenalidomide, and compares it to a standard treatment.
For: Relapsed/Refractory Follicular Lymphoma · Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)United States · Australia · Austria - RecruitingPHASE3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments, Iberdomide and Lenalidomide, after a stem cell transplant for multiple myeloma. It aims to find out which one works better at keeping the cancer under control following initial treatment.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is looking at a new medicine called talquetamab, combined with other treatments, for people with multiple myeloma. The main goal is to find safe doses and understand how well these combinations work together.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
This study compares a new cell therapy (ide-cel) plus standard maintenance medicine (lenalidomide) against lenalidomide alone for adults with newly diagnosed multiple myeloma. It's for those who haven't fully responded to their initial stem cell transplant.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
For: Follicular Lymphoma · Marginal Zone LymphomaUnited States · Australia · Austria - Active not recruitingPHASE1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is testing a new medicine called teclistamab, combined with other treatments, for people with multiple myeloma. Scientists want to find the safest and best doses of these combinations to treat the disease effectively.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE1
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
This study looks at a new combination treatment for newly diagnosed multiple myeloma. It combines an existing drug, belantamab mafodotin, with standard treatments (VRd) to see if it's safe and effective, and to find the best dose.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
This study is testing new treatments for two types of lymphoma, follicular and marginal zone lymphoma, when they have come back or not responded to previous treatment. It compares a drug called zanubrutinib combined with other medicines against a standard treatment to see which works best.
For: Relapsed/Refractory Follicular Lymphoma · Marginal Zone LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.
For: Diffuse Large B-cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
This study looks at new drug combinations for follicular lymphoma. It checks how safe they are, how well they work, and how the body handles them. Researchers are comparing different ways to give one of the drugs.
For: Follicular LymphomaUnited States · China · France - RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
For: Multiple MyelomaUnited States · Australia · Israel - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - RecruitingPHASE3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
This study compares two treatments for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. It looks at whether one combination of medicines (BRd) works better than another (DRd) to control the cancer and reduce its signs.
For: Multiple Myeloma · Newly Diagnosed Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
For: Relapsed/Refractory Follicular LymphomaUnited States · France · Germany - Active not recruitingPHASE1
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
This study looks at a new drug, ABBV-453, for multiple myeloma that has come back or not responded to previous treatments. Researchers want to see if it's safe, what side effects it might cause, and if it helps to control the disease.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Israel - AuthorisedTherapeutic confirmatory (Phase III)
LEISURE : Lenalidomide vs methotrexate in difficult-to-treat cutaneous lupus erythematosus (LEISURE trial): An assessor-blinded randomized clinical trial
This study, called LEISURE, is looking at two medicines, methotrexate and lenalidomide, to see which works best for people with severe skin lupus. Doctors want to see if these treatments can significantly reduce skin problems caused by lupus.
For: Cutaneous lupus erythematosusFrance - AuthorisedTherapeutic exploratory (Phase II)
Curing HIV: proof of concept randomized clinical trial with Pyrimethamine, Lenalidomide, TOpiramate (PLUTO)
This study, called PLUTO, is investigating if a combination of three existing medicines (lenalidomide, pyrimethamine, and topiramate) can help us find a cure for HIV. It's an early-stage trial looking at how these drugs affect the HIV virus in people and how safe they are.
For: HIV-1Netherlands - Active not recruitingPHASE3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
This study is for people in the UK with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has returned or not responded to previous treatments. It aims to see if adding an experimental drug, brentuximab vedotin, to two existing treatments (rituximab and lenalidomide) works better than the two existing treatments alone.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
For: LymphomaUnited States · Australia · Brazil - RecruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
For: Relapsed Follicular Lymphoma · Refractory Follicular LymphomaUnited Kingdom - Active not recruitingPHASE3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
This study is for adults with a type of blood cancer called follicular lymphoma, which has come back or isn't responding to treatment. It compares a new drug (Tazemetostat) with existing treatments to see if it's safe and helps people live longer without their cancer getting worse.
For: Relapsed/Refractory Follicular Lymphoma · Follicular Lymphoma · Refractory Follicular LymphomaUnited States · Australia · Belgium